GlassScriptPhysician profile
Rabi U Alam
NPI 1821288812
$1,229.26
in general payments reported to CMS, 2019-2025
24 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.48 · 2020: $29.76 · 2021: $65.51 · 2023: $35.83 · 2024: $627 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.45 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $104.42 | 2024-2025 | Austedo Xr, Austedo Xr |
| Neurelis, INC. | $99.96 | 2024-2025 | Valtoco |
| Sk Life Science, INC. | $98.99 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.27 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $82.36 | 2024-2025 | Gvoke Hypopen |
| Baxter Healthcare | $77.09 | 2024-2025 | Hillrom - Monarch Airway Clearance System |
| Philips North America LLC | $63.14 | 2024 | (8874) Incourage |
| Ucb, INC. | $62.63 | 2023-2025 | Briviact, Nayzilam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.19 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $47.92 | 2024-2025 | Cobenfy |
| Pfizer INC. | $42.06 | 2024 | |
| Melinta Therapeutics, LLC | $34.48 | 2019 | |
| Paratek Pharmaceuticals, INC. | $30.31 | 2025 | Nuzyra |
| Lundbeck LLC | $27.73 | 2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.54 | 2024 | |
| Mannkind Corporation | $26.78 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.62 | 2024 | Onpattro |
| Lilly USA, LLC | $24.86 | 2025 | Zepbound, Mounjaro |
| Viatris Specialty LLC | $20.96 | 2025 | Yupelri |
| Mylan Specialty L.P. | $20.59 | 2024 | Yupelri |
| Dexcom, INC. | $20.48 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $18.91 | 2024 | Rexulti |
| Smith+Nephew, INC. | $17.52 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabi Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.